The market for radiotherapy induced oral mucositis (RIOM), a common complication in head and neck cancer patients, is projected to expand across major global markets through 2036. Growth is driven by increased radiotherapy use, rising cancer incidence, and advances in targeted therapies that reduce inflammation and tissue damage, helping maintain uninterrupted cancer treatment. Current management focuses on symptom relief, but emerging drugs like Dusquetide and RRx-001 aim to prevent mucosal injury and accelerate healing. The US leads the market due to its large patient base and advanced oncology infrastructure, with Europe and Japan also showing growth potential. Market access and reimbursement will be key to adoption of new treatments that improve patient outcomes and reduce healthcare burdens.
The market for Radiotherapy Induced Oral Mucositis (RIOM) offers context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Oct 14, 2026 17:11 WIB: Out of 150 priced US health-sector stocks, 98 rose and 44 fell. Among notable movers, NUWE traded at USD 0.61 with a 2.50% decline and a typical hold time of 27 days, contrasting with GH at USD 158.20, down 2.40% but with 100% buy order activity and a much shorter hold time of 3 days. ARWR gained 2.25% to USD 59.44 with a 5-day hold time, showing varied investor interest across these stocks.
CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...
Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...
Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...
DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...
Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...
